Apollo Management Holdings’s Pacira BioSciences PCRX Stock Holding History

Apollo Management Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,114	Closed	-$61.8K	–	58
2024 Q1	$61.8K	Hold	2,114	–	–	﹤0.01%	54
2023 Q4	$71.3K	Hold	2,114	–	–	﹤0.01%	51
2023 Q3	$64.9K	Hold	2,114	–	–	﹤0.01%	65
2023 Q2	$84.7K	Hold	2,114	–	–	﹤0.01%	76
2023 Q1	$86.3K	Hold	2,114	–	–	﹤0.01%	121
2022 Q4	$82K	Hold	2,114	–	–	﹤0.01%	147
2022 Q3	$112K	Sell	2,114 -8,754	-81%	-$487K	﹤0.01%	177
2022 Q2	$634K	Buy	+10,868	New	+$712K	﹤0.01%	189

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apollo Management Holdings's PCRX Position: Q2 2024 in Review

Apollo Management Holdings sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 2,114 shares — an estimated $61.8K sold.

Apollo Management Holdings first reported a position in PCRX in Q2 2022 and held it in 8 quarters. The position peaked at $634K in Q2 2022. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Apollo Management Holdings reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Apollo Management Holdings sold 2,114 Pacira BioSciences shares in Q2 2024, an estimated $61.8K.
Apollo Management Holdings first reported a position in Pacira BioSciences in Q2 2022 and held it in 8 quarters.
Apollo Management Holdings's Pacira BioSciences position peaked at $634K in Q2 2022.
280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Apollo Management Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.